An Overview of Toxicogenomics Approaches to Mechanistically Understand and Predict Kidney Toxicity

Benedetti, Giulia; Water, Bob van de; Graauw, Marjo de

doi:10.1016/b978-0-12-397862-2.00011-5

Cited by 2 publications

(2 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding toxicity and the application of proteomics to finding biomarkers of toxicity remains a key initiative within the drug development arena, such as drug‐induced liver injury (DILI) and kidney injury . Toxicoproteomics remains a relatively niche area however and the number of recent publications relating to adverse drug events is finite .…”

Section: Applications In (Pre‐)clinical Drug Developmentmentioning

confidence: 99%

Proteomics in pharmaceutical research and development

Cutler

Voshol

2015

Proteomics Clinical Apps

View full text Add to dashboard Cite

In the 20 years since its inception, the evolution of proteomics in pharmaceutical industry has mirrored the developments within academia and indeed other industries. From initial enthusiasm and subsequent disappointment in global protein expression profiling, pharma research saw the biggest impact when relating to more focused approaches, such as those exploring the interaction between proteins and drugs. Nowadays, proteomics technologies have been integrated in many areas of pharmaceutical R&D, ranging from the analysis of therapeutic proteins to the monitoring of clinical trials. Here, we review the development of proteomics in the drug discovery process, placing it in a historical context as well as reviewing the current status in light of the contributions to this special issue, which reflect some of the diverse demands of the drug and biomarker pipelines.

show abstract

Section: Applications In (Pre‐)clinical Drug Developmentmentioning

confidence: 99%

Proteomics in pharmaceutical research and development

Cutler

Voshol

2015

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“… 2 In fact, drug-induced AKI is a long-term concern in clinical pharmacology and accounts for 19% to 26% of cases of AKI in clinical practice, 3 which is a major reason for post-marketing withdrawals of medicinal products. 4 , 5 At present, serum creatinine (SCr) and blood urea nitrogen (BUN) are conventional nephrotoxicity biomarkers for the evaluation of drug-induced AKI, 6 but they are not available for early diagnosis 7 , 8 and usually affected by a variety of other diseases. 9 Moreover, a limited number of early biomarkers have been explored during the AKI process.…”

Section: Introductionmentioning

confidence: 99%